title: Imaging of colorectal carcinoma with radiolabeled antibodies.
abstract: Colorectal cancer has been the tumor type most frequently studied with radiolabeled antibodies. Among the various antibodies, a majority of patients with colorectal cancer have received xenogeneic polyclonal or monoclonal antibodies against carcino-embryonic antigen. This review summarizes the current status of colorectal cancer imaging with radiolabeled antibodies, ie, radioimmunodetection (RAID), and examines the published studies involving carcinoembryonic antigen (CEA) antibodies and 17-1A, 19-9, and B72.3, and other monoclonal antibodies. In order to better address the issue of the current and future clinical usefulness of this emerging technology, particular attention is given to the protocols, methods, and results of the published studies. Despite differences in study parameters, antibodies and forms, labels, administration routes and doses, and scanning instruments and methods, it has been found that (1) almost no adverse reactions have been evident; (2) antibody fragments are preferred over whole immunoglobulin G reagents because they achieve higher tumor-to-background ratios earlier, thus reducing or precluding the need for dual-isotope subtraction methods or long delays before imaging; (3) use of antibody fragments, including the monovalent Fab' form, permits imaging with short-lived radionuclides of excellent photon properties, such as 123I and 99mTc; (4) circulating antigens against which the imaging antibody is directed can complex with the injected antibody, but such complexes have not prevented successful RAID; (5) patients with high serum titers of the appropriate antigen target usually have higher rates of positive RAID; (6) patients who are seronegative for the tumor antigen being studied can have positive RAID findings, which can represent the detection of occult lesions; (7) single photon emission computed tomography appears to provide better image resolution than planar scanning; (8) regardless of the sensitivity reported in any particular study, almost all investigators have observed the disclosure of occult neoplasms by RAID; and (9) RAID, a more functional test of usually high specificity, can complement other radiological methods, such as computed tomography scans, which are limited to structural information.
authors.affiliation: Center for Molecular Medicine and Immunology, New Jersey Medical School, Newark.
authors.forename: D M
authors.initials: DM
authors.lastname: Goldenberg
authors.forename: H
authors.initials: H
authors.lastname: Goldenberg
authors.forename: R M
authors.initials: RM
authors.lastname: Sharkey
authors.forename: R E
authors.initials: RE
authors.lastname: Lee
authors.forename: E
authors.initials: E
authors.lastname: Higgenbotham-Ford
authors.forename: J A
authors.initials: JA
authors.lastname: Horowitz
authors.forename: T C
authors.initials: TC
authors.lastname: Hall
authors.forename: C M
authors.initials: CM
authors.lastname: Pinsky
authors.forename: H J
authors.initials: HJ
authors.lastname: Hansen
mesh_terms: D000911:Antibodies, Monoclonal; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging*; D006801:Humans; D011868:Radioisotopes; D014055:Tomography, Emission-Computed
chemical_list: D000911:Antibodies, Monoclonal; D011868:Radioisotopes